SCHEMBL24460465

SCHEMBL24460465

FC(F)(F)c1ccc2c(c1)CNCCS2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RYR2 Q92736 2/20 0.55
KCNH2 Q12809 1/20 0.55
ASIC3 Q9UHC3 1/20 0.41
PTPN5 P54829 1/20 0.40
PNMT P11086 4/20 0.39
CTSL P07711 1/20 0.39
HTR2A P28223 3/20 0.37
HTR2C P28335 3/20 0.37
HTR2B P41595 3/20 0.37
CYBB P04839 1/20 0.36
NOX3 Q9HBY0 1/20 0.36
NOX4 Q9NPH5 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
TDP2 O95551 1/20 0.36
CHRNB2 P17787 2/20 0.35
CHRNA4 P43681 2/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL26932168 0.98 RYR2 (0.54) RYR2KCNH2ASIC3PTPN5PNMT
SCHEMBL24460345 0.89 RYR2 (0.54) RYR2KCNH2ASIC3PTPN5PNMT
SCHEMBL14691898 0.78 RYR2 (0.59) RYR2KCNH2PNMTCTSLHTR2A
SCHEMBL7999750 0.77 RYR2 (0.67) RYR2KCNH2CTSLHTR2C
Bromide SCHEMBL3425744 0.76 RYR2 (0.65) RYR2KCNH2CTSLHTR2C
SCHEMBL28461427 0.75 RYR2 (0.59) RYR2KCNH2ASIC3PNMTCTSL
SCHEMBL8134941 0.75 RYR2 (0.59) RYR2KCNH2PNMTHTR2AHTR2C
SCHEMBL2062318 0.75 RYR2 (0.59) RYR2KCNH2PNMTHTR2AHTR2C
SCHEMBL2600211 0.75 RYR2 (0.64) RYR2KCNH2PNMTCTSLHTR2A
SCHEMBL2591547 0.74 RYR2 (0.62) RYR2KCNH2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399324-A1 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS RYCARMA THERAPEUTICS, INC. 2023-12-14 US disclosed
WO-2022108945-A1 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS ARMGO PHARMA, INC. (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399324-A1 AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS RYR2, RYR1, ATP2A1 RYR2 1/4885KCNH2 605/4885ASIC3 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.